Cargando…
Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
OBJECTIVES: The etiology of depression remains unknown. There is, however, a growing body of evidence that cytokines are involved in the pathophysiology of depression. The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317346/ https://www.ncbi.nlm.nih.gov/pubmed/28243095 http://dx.doi.org/10.2147/NDT.S123121 |
_version_ | 1782508987924611072 |
---|---|
author | Yoshimura, Reiji Katsuki, Asuka Atake, Kiyokazu Hori, Hikaru Igata, Ryohei Konishi, Yuki |
author_facet | Yoshimura, Reiji Katsuki, Asuka Atake, Kiyokazu Hori, Hikaru Igata, Ryohei Konishi, Yuki |
author_sort | Yoshimura, Reiji |
collection | PubMed |
description | OBJECTIVES: The etiology of depression remains unknown. There is, however, a growing body of evidence that cytokines are involved in the pathophysiology of depression. The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement of the depressive state. SUBJECTS AND METHODS: Thirty patients who met the DSM-IV criteria for major depressive disorder (MDD) were enrolled in the study. Thirteen were male and 17 were female, and their ages ranged from 26 to 70 years (mean ± standard deviation 45.0±14.2). The patients were treated with fluvoxamine for 8 weeks. The dosages of fluvoxamine varied among the patients and, based on ethical considerations, were not fixed. RESULTS: The fluvoxamine doses were positively related to plasma fluvoxamine levels (r =0.8798, P<0.001). A significant correlation was observed between the patients’ plasma IL-6 levels and their 17-item Hamilton Rating Scale for Depression (HAMD17) scores (r =0.4555, P=0.0010). A positive correlation was found between the delta plasma IL-6 (week 0–week 8) and the delta HAMD17 (week 0–week 8) (r =0.5226, P=0.002). CONCLUSION: Effect of fluvoxamine on IL-6 is partially associated with its clinical efficacy for MDD. |
format | Online Article Text |
id | pubmed-5317346 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53173462017-02-27 Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder Yoshimura, Reiji Katsuki, Asuka Atake, Kiyokazu Hori, Hikaru Igata, Ryohei Konishi, Yuki Neuropsychiatr Dis Treat Original Research OBJECTIVES: The etiology of depression remains unknown. There is, however, a growing body of evidence that cytokines are involved in the pathophysiology of depression. The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement of the depressive state. SUBJECTS AND METHODS: Thirty patients who met the DSM-IV criteria for major depressive disorder (MDD) were enrolled in the study. Thirteen were male and 17 were female, and their ages ranged from 26 to 70 years (mean ± standard deviation 45.0±14.2). The patients were treated with fluvoxamine for 8 weeks. The dosages of fluvoxamine varied among the patients and, based on ethical considerations, were not fixed. RESULTS: The fluvoxamine doses were positively related to plasma fluvoxamine levels (r =0.8798, P<0.001). A significant correlation was observed between the patients’ plasma IL-6 levels and their 17-item Hamilton Rating Scale for Depression (HAMD17) scores (r =0.4555, P=0.0010). A positive correlation was found between the delta plasma IL-6 (week 0–week 8) and the delta HAMD17 (week 0–week 8) (r =0.5226, P=0.002). CONCLUSION: Effect of fluvoxamine on IL-6 is partially associated with its clinical efficacy for MDD. Dove Medical Press 2017-02-14 /pmc/articles/PMC5317346/ /pubmed/28243095 http://dx.doi.org/10.2147/NDT.S123121 Text en © 2017 Yoshimura et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Yoshimura, Reiji Katsuki, Asuka Atake, Kiyokazu Hori, Hikaru Igata, Ryohei Konishi, Yuki Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder |
title | Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder |
title_full | Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder |
title_fullStr | Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder |
title_full_unstemmed | Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder |
title_short | Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder |
title_sort | influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317346/ https://www.ncbi.nlm.nih.gov/pubmed/28243095 http://dx.doi.org/10.2147/NDT.S123121 |
work_keys_str_mv | AT yoshimurareiji influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT katsukiasuka influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT atakekiyokazu influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT horihikaru influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT igataryohei influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT konishiyuki influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder |